» Articles » PMID: 20064286

NCCN Task Force: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes

Overview
Specialty Oncology
Date 2010 Jan 13
PMID 20064286
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force to critically review the evidence for iron chelation and the rationale for treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). The task force was charged with addressing issues related to tissue iron toxicity; the role of MRI in assessing iron overload; the rationale and role of treating transfusional iron overload in patients with MDS; and the impact of iron overload on bone marrow transplantation. This report summarizes the background data and ensuing discussion from the NCCN Task Force meeting on transfusional iron overload in MDS.

Citing Articles

Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.

An W, Feola M, Levy M, Aluri S, Ruiz-Martinez M, Sridharan A Elife. 2023; 12.

PMID: 38153418 PMC: 10754500. DOI: 10.7554/eLife.83103.


Quercetin attenuates neurotoxicity induced by iron oxide nanoparticles.

Bardestani A, Ebrahimpour S, Esmaeili A, Esmaeili A J Nanobiotechnology. 2021; 19(1):327.

PMID: 34663344 PMC: 8522232. DOI: 10.1186/s12951-021-01059-0.


Myelodysplastic syndromes: moving towards personalized management.

Hellstrom-Lindberg E, Tobiasson M, Greenberg P Haematologica. 2020; 105(7):1765-1779.

PMID: 32439724 PMC: 7327628. DOI: 10.3324/haematol.2020.248955.


Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Patnaik M, Tefferi A Am J Hematol. 2019; 94(4):475-488.

PMID: 30618061 PMC: 6408294. DOI: 10.1002/ajh.25397.


Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes.

Shah J, McKiernan P J Adv Pract Oncol. 2018; 7(7):707-717.

PMID: 29670807 PMC: 5902151.